

1 **Improved performance of saliva for the detection of the B.1.351** 2 **variant in South Africa**

3

4 Abstract:

5 Assessment of the unknown performance of saliva for the detection of the novel
6 SARS-CoV-2 variant of concern (VOC) B.1.351 (501Y.V2) lineage is essential as
7 saliva has been shown to be an equivalent, less invasive and a less costly
8 alternative to nasopharyngeal swabs for the molecular detection of SARS-CoV-2
9 infection in pre-variant studies. Between 1st August 2020 and 16th January 2021, we
10 enrolled 410 eligible ambulatory participants who presented to Groote Schuur
11 Hospital (GSH) in Cape Town, South Africa for SARS-CoV-2 testing. Of these, 300
12 were enrolled prior to, and 110 after, the initial detection and replacement of wild-
13 type by the B.1.351 variant. All participants provided a supervised self-collected mid-
14 turbinate (MT) and saliva (SA) swab, in addition to the standard HCW collected NP
15 swab which were all tested by RT-PCR in an accredited diagnostic laboratory.
16 Positive percent agreement to NP swab for SA swabs pre- and post-variant were
17 51.5% and 72.5% respectively while these values for MT swabs were 75.8% and
18 77.5%. The negative percent agreement for all swab types during all periods was
19 >98%. The basis for this marked improvement of SA swabs as a diagnostic sample
20 for B.1.351 virus is still being investigated.

21

22 Body:

23 In December 2020, South Africa (SA) faced a surge in COVID-19 cases, which was
24 associated with the replacement of previous circulating lineages with a novel SARS-
25 CoV-2 variant of concern (VOC) B.1.351 (501Y.V2) lineage¹. Preliminary analyses

26 suggest that this variant, defined by 3 mutations at key sites in the receptor-binding
27 domain, may have functional significance including increased transmissibility¹. In the
28 assessment of multiple diagnostic sample types to reduce the need for directed
29 healthcare worker (HCW) performed sampling, saliva has been shown to be
30 equivalent, safer and a less costly alternative to nasopharyngeal (NP) swabs for
31 molecular confirmation of SARS-CoV-2 infection^{2,3}. Its performance in the detection
32 of VOC virus is, however, unknown.

33

34 Between 1st August 2020 and 16th January 2021, we enrolled 410 eligible ambulatory
35 participants who presented to Groote Schuur Hospital (GSH) in Cape Town, South
36 Africa for SARS-CoV-2 testing. Of these, 300 were enrolled prior to, and 110 after,
37 the initial detection and replacement of the B.1.351 variant. All participants provided
38 a supervised self-collected mid-turbinate (MT) and saliva (SA) swab, in addition to
39 the standard HCW collected NP swab which were tested by RT-PCR⁴ in an
40 accredited diagnostic laboratory. Assessment of the diagnostic validity of MT and SA
41 relative to NP swabs (Fig. 1A) was assessed by comparing the mean cycle threshold
42 (Ct) differences (Fig. 1B and C), pre-test probability (Fig 1D). Whole genome
43 sequencing of suitable specimens (Fig. 1E), was performed.

44

45 Notably, a noted improvement in the positive percent agreement (PPA) for SA but
46 not MT relative to NP swabs, for the two cohorts was documented. The reasons for
47 the significant change in SA PPA are currently unknown. Possibilities include
48 changes in tissue tropism⁵ associated with the VOC B.1.351, and while increased
49 viral replication in salivary glands would be expected to decrease the mean Ct value
50 to a greater extent than for NP swabs post B.1.351 lineage emergence, this was not

51 evident. However, a potential explanation would be the presence of greater RNA
52 quantities of VOC B.1.351 reflected by decreased mean Ct values for all sample
53 types, which may support the preliminary modelling-based finding of increased
54 transmissibility¹. Whilst altered test-seeking behavior in the study population cannot
55 be excluded the inclusion criteria remained the same throughout the study.

56

57 Whilst further WGS studies are ongoing to determine compartmentalized replication
58 and to inform diagnostic preferences concurrent to public health interventions,
59 knowledge of distinct oral and oropharyngeal shedding dynamics and viral burden
60 through the continuum of SARS-CoV-2 infections is warranted.


61

A


	PPA	95% CI	NPA	95% CI	PPV	95% CI	NPV	95% CI	Cohen's kappa
SA pre-B.1.351	51.5	35.22-67.50	98.5	96.21-99.42	81.0	60.00-92.33	94.3	90.89-96.44	0.60
SA post-B.1.351	72.5	57.17-83.89	98.5	92.02-99.92	96.7	83.33-99.83	85.7	76.20-91.83	0.75
MT pre-B.1.351	75.8	58.98-87.17	99.3	97.31-99.87	92.6	76.63-98.68	97.1	94.33-98.51	0.82
MT post-B.1.351	77.5	62.50-87.68	100	94.58-100.0	100	88.97-100.0	88.2	79.00-93.64	0.81

SA: Saliva; MT: Mid-turbinate; NP: Nasopharyngeal PPA: Positive percent agreement; NPA: Negative percent agreement; PPV: Positive predictive value; NPV: Negative predictive value; 95% CI: 95% Confidence Interval; Cohen Kappa: The following nomenclature were used to describe the relative strength of agreement associated with kappa statistics: 0 = poor; 0-0.2 = slight; 0.21-0.4 = fair; 0.41-0.6 = moderate; 0.61-0.8 = substantial; and 0.81-1 = almost perfect.


B




C



D



E



63

64 Figure 1. A: Positive and negative percent agreement to nasopharyngeal (NP) swab
65 as well as positive and negative predictive value of saliva (SA) and mid-turbinate
66 (MT) self-administered swabs as a diagnostic sample for SARS-CoV-2 PCR prior to
67 (n=33/300) and after (n=40/107) the emergence of the B.1.351 lineage. Post-
68 emergence, 3 proven non-B.1.351 lineage virus infected participants were excluded.
69 The likelihood ratio of having a positive SA swab result pre- and post-emergence of
70 the B.1.351 lineage for participants with a positive NP swab result was 34 and 48
71 respectively. Confidence intervals were calculated using the Wilson-Brown method.

72

73 B and C: Mean cycle threshold (Ct) values for SA, MT and NP swabs are shown with
74 1 standard deviation error bars.

75 B. Pre-B.1.351 emergence [34.35 (95% CI: 32.67-36.02), 30.31 (95% CI: 28.34-
76 32.27) and 30.44 (95%: 28.65-32.22) respectively]

77 C. Post-emergence [30.96 (95% CI: 29.36-32.56), 27.84 (95% CI: 25.79-29.88),
78 27.16 (95% CI: 25.50-28.83) respectively]. The mean Ct SA values decreased by
79 3.39 and a comparable 2.47 and 3.28 for MT and NP, respectively. Paired t-tests
80 were used to compare swab Ct values. *: P-value < 0.05, **: P-value <0.01, ***: P-
81 value <0.001, ****: P-value <0.0001.

82

83 D: Longitudinal number of all tests performed and positive percentage of SARS-CoV-
84 2 tests over the study period at the GSH testing centre. Participants in this study are
85 included.

86

87 E: Whole genome sequencing. Longitudinal number of isolates from each clade
88 including the number of viral isolates not deemed suitable for sequencing (Ct values
89 ≥ 30).

90

91 Authors and affiliation

92

93 Chun Yat Chu, MB.ChB.

94 University of Cape Town

95 Cape Town, South Africa

96 chunyat.chu@nhls.ac.za

97

98 Gert Marais, MB.ChB, MSc

99 University of Cape Town

100 Cape Town, South Africa

101 gert.marais16@alumni.imperial.ac.uk

102

103 Christoffel Opperman, MB.ChB, BSc

104 University of Cape Town

105 Cape Town, South Africa

106

107 Deelan Doolabh, MSc

108 University of Cape Town

109 Cape Town, South Africa

110

111 Arash Iranzadeh

112 University of Cape Town

113 Cape Town, South Africa

114

115 Carisa Marais, MB.ChB.

116 University of Cape Town

117 Cape Town, South Africa

118

119 Helen Cox, Ph.D.

120 University of Cape Town

121 Cape Town, South Africa

122

123 Carolyn Williamson, Ph.D.

124 University of Cape Town

125 Cape Town, South Africa

126

127 Diana Hardie, MMed

128 University of Cape Town

129 Cape Town, South Africa

130

131 Adrian Brink, MMed

132 University of Cape Town

133 Cape Town, South Africa

134

135 Funding

136 Supported by the University of Cape Town Wellcome Centre for Infectious Diseases
137 Research in Africa (CIDRI-Africa)

138

139 Reference

140 1. Tegally H, Wilkinson E, Giovanetti M, et al. Emergence of a SARS-CoV-2 variant
141 of concern with mutations in spike glycoprotein. Nature 2021.[https://doi.org/10.1038/](https://doi.org/10.1038/s41586-021-03402-9)
142 [s41586-021-03402-9](https://doi.org/10.1038/s41586-021-03402-9).

143 2. Tu Y-P, Jennings R, Hart B, et al. Swabs collected by patients or health care
144 workers for SARS-CoV-2 testing. New England Journal of Medicine 2020;383:494-6.

145 3. Bastos ML, Perlman-Arrow S, Menzies D, Campbell JR. The Sensitivity and Costs
146 of Testing for SARS-CoV-2 Infection With Saliva Versus Nasopharyngeal Swabs : A
147 Systematic Review and Meta-analysis. Ann Intern Med 2021:M20-6569.

148 4. Marais G, Naidoo M, Hsiao N-y, Valley-Omar Z, Smuts H, Hardie D. The
149 implementation of a rapid sample preparation method for the detection of SARS-
150 CoV-2 in a diagnostic laboratory in South Africa. PloS one 2020;15:e0241029

151 5. Huang N, Perez P, Kato T, et al. Integrated single-cell atlases reveal an oral
152 SARS-CoV-2 infection and transmission axis. medRxiv. 27 October, 2020.

153 doi: 10.1101/2020.10.26.20219089. preprint.